Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABC
ABcann Global
C$0.00
C$0.00
C$0.00
N/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.04
+2.0%
$1.96
$1.60
$2.54
$786.79M1.031.35 million shs1.94 million shs
Genius Group Limited stock logo
GNS
Genius Group
$1.44
+5.1%
$0.52
$0.21
$3.20
$102.99M10.984.23 million shs8.01 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00%+7.37%+5.70%+19.30%-12.07%
Genius Group Limited stock logo
GNS
Genius Group
0.00%+45.45%+282.78%+465.37%-48.20%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+4.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABC
ABcann Global
N/AN/AN/AN/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
2.2876 of 5 stars
0.05.00.00.01.90.02.5
Genius Group Limited stock logo
GNS
Genius Group
1.8478 of 5 stars
0.05.00.00.03.01.70.6
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABC
ABcann Global
0.00
N/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00
N/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABC
ABcann Global
N/AN/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
$117.61M6.69$0.00 per share4,384.08$2.90 per share0.70
Genius Group Limited stock logo
GNS
Genius Group
$7.91M13.02N/AN/A$1.23 per share1.17
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABC
ABcann Global
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
$41.08M$0.1315.6968.00N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)
Genius Group Limited stock logo
GNS
Genius Group
-$24.88MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest GNS, ABC, MOR, and CRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Cronos Group Inc. stock logo
CRON
Cronos Group
$0.01$0.02+$0.01$0.02$45.44 million$33.62 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABC
ABcann Global
N/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABC
ABcann Global
N/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
27.80
26.75
Genius Group Limited stock logo
GNS
Genius Group
0.13
3.65
3.61
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
ABC
ABcann Global
N/A
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Genius Group Limited stock logo
GNS
Genius Group
14.28%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
ABC
ABcann Global
N/A
Cronos Group Inc. stock logo
CRON
Cronos Group
7.30%
Genius Group Limited stock logo
GNS
Genius Group
51.19%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABC
ABcann Global
N/AN/AN/ANot Optionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450385.68 million357.53 millionOptionable
Genius Group Limited stock logo
GNS
Genius Group
48071.52 million34.91 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cronos Group stock logo

Cronos Group NASDAQ:CRON

$2.04 +0.04 (+2.00%)
Closing price 07/3/2025 03:16 PM Eastern
Extended Trading
$2.04 0.00 (-0.25%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Genius Group stock logo

Genius Group NYSEAMERICAN:GNS

$1.44 +0.07 (+5.11%)
As of 07/3/2025 05:00 PM Eastern

Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 07/3/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.